In a patient with a long‑standing athletic heart (>20 years) who now shows hypertrophic cardiomyopathy‑type myocardial thickening and a possible left‑ventricular outflow tract obstruction, would myosin‑inhibitor therapy (e.g., mavacamten or aficamten) be beneficial?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Myosin Inhibitor Therapy in Athletic Heart with HCM-Like Features and Possible Obstruction

The critical first step is to definitively distinguish true hypertrophic cardiomyopathy from physiologic athletic remodeling, because myosin inhibitors (mavacamten, aficamten) are only indicated for confirmed obstructive HCM and would be inappropriate—and potentially harmful—in pure athletic heart. 1

Diagnostic Clarification Required

Your 20+ year athletic heart with "HCM-like thickening" and "possible obstruction" represents a diagnostic gray zone that must be resolved before considering myosin inhibitors:

Features Favoring True HCM Over Athletic Heart:

  • Left ventricular wall thickness >15 mm (athletic heart rarely exceeds 13-14 mm)
  • Asymmetric septal hypertrophy (athletic heart shows concentric patterns)
  • Resting or provoked LVOT gradient ≥30 mmHg
  • Left atrial enlargement disproportionate to LV size
  • Diastolic dysfunction beyond what deconditioning would explain
  • Positive genetic testing for sarcomeric mutations
  • Late gadolinium enhancement on cardiac MRI (suggests fibrosis, not seen in athletic heart)
  • Failure of hypertrophy to regress after 3-6 months of detraining

Critical Diagnostic Steps:

  1. Cardiac MRI with late gadolinium enhancement to assess for fibrosis 2
  2. Exercise stress echocardiography to provoke latent LVOT obstruction 3
  3. Genetic testing for sarcomeric mutations
  4. Consider 3-6 month detraining period if diagnosis remains uncertain (athletic heart will regress; HCM will not)

If Confirmed Obstructive HCM: Myosin Inhibitor Eligibility

Myosin inhibitors are Class 1 recommended for adults with obstructive HCM who remain symptomatic despite beta-blockers or non-dihydropyridine calcium channel blockers. 1

Specific Criteria for Mavacamten or Aficamten:

Inclusion criteria:

  • Confirmed HCM diagnosis (not athletic heart)
  • LVOT gradient ≥30 mmHg (resting or provoked with Valsalva) 4
  • LVEF ≥55% at baseline 2
  • Persistent symptoms (dyspnea, chest pain, near-syncope) despite first-line therapy
  • Adult patient (not approved for pediatrics)

Absolute contraindications:

  • LVEF <55% 2, 4
  • Pregnancy or potential pregnancy (teratogenic) 1, 5, 4
  • Pure athletic heart without true HCM

Monitoring Requirements if Initiated

Mandatory echocardiographic surveillance is required due to risk of excessive LVEF reduction (5.7-10% of patients). 2, 1

Monitoring Protocol:

  • Monthly echocardiograms for first 3 months
  • Every 3 months thereafter 2
  • Temporarily discontinue if LVEF drops <50% 2, 4
  • Permanently discontinue if LVEF <30% 2

Clinical Efficacy Data

Mavacamten reduces LVOT gradients by 35-49 mmHg and improves symptoms, but only 37% of patients meet primary efficacy endpoints despite dose titration. 2 The remaining patients show partial benefit with gradient reduction and biomarker improvement 2.

Aficamten demonstrates similar gradient reductions (-35 mmHg resting, -48 mmHg Valsalva) with comparable LVEF safety profile. 6

Alternative Therapies if Myosin Inhibitors Inappropriate

If this proves to be athletic heart or if LVEF is borderline:

First-line options:

  • Non-vasodilating beta-blockers (metoprolol, atenolol) titrated to physiologic effect 1, 2
  • Verapamil or diltiazem if beta-blockers ineffective (caution: avoid if very high gradients >100 mmHg or severe symptoms at rest) 1, 7

Second-line:

  • Disopyramide (with AV nodal blocker to prevent rapid AF conduction) 1

Invasive options:

  • Surgical myectomy or alcohol septal ablation at experienced centers if medical therapy fails 2, 1

Critical Pitfalls to Avoid

  1. Do not use myosin inhibitors without confirmed HCM diagnosis—athletic heart requires no treatment beyond possible activity modification
  2. Do not initiate if LVEF <55%—risk of symptomatic heart failure 2
  3. Avoid vasodilators (ACE inhibitors, ARBs, dihydropyridine CCBs) if obstruction confirmed—these worsen LVOT gradients 1, 7
  4. Do not skip mandatory echocardiographic monitoring—LVEF reduction can occur unpredictably 2, 1

Bottom line: Resolve the athletic heart vs. true HCM question definitively before considering myosin inhibitors. If confirmed obstructive HCM with LVEF ≥55% and persistent symptoms despite conventional therapy, myosin inhibitors are appropriate and guideline-recommended, but require rigorous monitoring. 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.